Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection.

Antoine TE, Mishra YK, Trigilio J, Tiwari V, Adelung R, Shukla D.

Antiviral Res. 2012 Dec;96(3):363-75. doi: 10.1016/j.antiviral.2012.09.020. Epub 2012 Oct 6.

2.

Virostatic potential of micro-nano filopodia-like ZnO structures against herpes simplex virus-1.

Mishra YK, Adelung R, Röhl C, Shukla D, Spors F, Tiwari V.

Antiviral Res. 2011 Nov;92(2):305-12. doi: 10.1016/j.antiviral.2011.08.017. Epub 2011 Aug 26.

3.

Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo.

Tiwari V, Liu J, Valyi-Nagy T, Shukla D.

J Biol Chem. 2011 Jul 15;286(28):25406-15. doi: 10.1074/jbc.M110.201103. Epub 2011 May 19.

4.

HVEM and nectin-1 are the major mediators of herpes simplex virus 1 (HSV-1) entry into human conjunctival epithelium.

Akhtar J, Tiwari V, Oh MJ, Kovacs M, Jani A, Kovacs SK, Valyi-Nagy T, Shukla D.

Invest Ophthalmol Vis Sci. 2008 Sep;49(9):4026-35. doi: 10.1167/iovs.08-1807. Epub 2008 May 23.

5.

Contortrostatin, a homodimeric disintegrin isolated from snake venom inhibits herpes simplex virus entry and cell fusion.

Hubbard S, Choudhary S, Maus E, Shukla D, Swenson S, Markland FS Jr, Tiwari V.

Antivir Ther. 2012;17(7):1319-26. doi: 10.3851/IMP2291. Epub 2012 Aug 8.

PMID:
22875654
6.

Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus.

Levendosky K, Mizenina O, Martinelli E, Jean-Pierre N, Kizima L, Rodriguez A, Kleinbeck K, Bonnaire T, Robbiani M, Zydowsky TM, O'Keefe BR, Fernández-Romero JA.

Antimicrob Agents Chemother. 2015 Dec;59(12):7290-8. doi: 10.1128/AAC.01816-15. Epub 2015 Sep 14.

7.

Synthetic analogues of bovine bactenecin dodecapeptide reduce herpes simplex virus type 2 infectivity in mice.

Shestakov A, Jenssen H, Hancock RE, Nordström I, Eriksson K.

Antiviral Res. 2013 Nov;100(2):455-9. doi: 10.1016/j.antiviral.2013.08.019. Epub 2013 Sep 5.

PMID:
24012999
8.

Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites.

Wang A, Chen F, Wang Y, Shen M, Xu Y, Hu J, Wang S, Geng F, Wang C, Ran X, Su Y, Cheng T, Wang J.

J Virol. 2013 Mar;87(5):2835-45. doi: 10.1128/JVI.02209-12. Epub 2012 Dec 26.

9.

Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: mechanism of antiviral action.

Ceña-Diez R, Vacas-Córdoba E, García-Broncano P, de la Mata FJ, Gómez R, Maly M, Muñoz-Fernández MÁ.

Int J Nanomedicine. 2016 May 19;11:2147-62. doi: 10.2147/IJN.S95301. eCollection 2016.

11.

A 3-O-sulfated heparan sulfate binding peptide preferentially targets herpes simplex virus 2-infected cells.

Ali MM, Karasneh GA, Jarding MJ, Tiwari V, Shukla D.

J Virol. 2012 Jun;86(12):6434-43. doi: 10.1128/JVI.00433-12. Epub 2012 Apr 4.

12.

A sugar binding protein cyanovirin-N blocks herpes simplex virus type-1 entry and cell fusion.

Tiwari V, Shukla SY, Shukla D.

Antiviral Res. 2009 Oct;84(1):67-75. doi: 10.1016/j.antiviral.2009.07.014. Epub 2009 Aug 7.

13.

Tin oxide nanowires suppress herpes simplex virus-1 entry and cell-to-cell membrane fusion.

Trigilio J, Antoine TE, Paulowicz I, Mishra YK, Adelung R, Shukla D.

PLoS One. 2012;7(10):e48147. doi: 10.1371/journal.pone.0048147. Epub 2012 Oct 24.

14.

Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication.

Gong Y, Matthews B, Cheung D, Tam T, Gadawski I, Leung D, Holan G, Raff J, Sacks S.

Antiviral Res. 2002 Aug;55(2):319-29.

PMID:
12103432
15.

Inhibition of myosin light chain kinase can be targeted for the development of new therapies against herpes simplex virus type-1 infection.

Antoine TE, Shukla D.

Antivir Ther. 2014;19(1):15-29. doi: 10.3851/IMP2661. Epub 2013 Jun 28.

PMID:
23813409
16.

Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread.

Lin LT, Chen TY, Chung CY, Noyce RS, Grindley TB, McCormick C, Lin TC, Wang GH, Lin CC, Richardson CD.

J Virol. 2011 May;85(9):4386-98. doi: 10.1128/JVI.01492-10. Epub 2011 Feb 9.

17.

The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice.

Donalisio M, Quaranta P, Chiuppesi F, Pistello M, Cagno V, Cavalli R, Volante M, Bugatti A, Rusnati M, Ranucci E, Ferruti P, Lembo D.

Biomaterials. 2016 Apr;85:40-53. doi: 10.1016/j.biomaterials.2016.01.055. Epub 2016 Jan 27.

PMID:
26854390
18.

Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection.

Orlowski P, Tomaszewska E, Gniadek M, Baska P, Nowakowska J, Sokolowska J, Nowak Z, Donten M, Celichowski G, Grobelny J, Krzyzowska M.

PLoS One. 2014 Aug 12;9(8):e104113. doi: 10.1371/journal.pone.0104113. eCollection 2014.

19.

Effect of black tea extract on herpes simplex virus-1 infection of cultured cells.

Cantatore A, Randall SD, Traum D, Adams SD.

BMC Complement Altern Med. 2013 Jun 18;13:139. doi: 10.1186/1472-6882-13-139.

20.

Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro.

Schuhmacher A, Reichling J, Schnitzler P.

Phytomedicine. 2003;10(6-7):504-10.

PMID:
13678235

Supplemental Content

Support Center